Anya Biopharm Inc. (TPEX:7776)
Taiwan · Delayed Price · Currency is TWD 32.35
+1.45 (4.69%)
At close: Sep 2, 2026
Anya Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 13.06 | 16.27 | 21.6 | 2.32 | 2.5 | |
Revenue Growth | -47.41% | -24.66% | 831.26% | -7.09% | - |
Cost of Revenue | 0.14 | 0.14 | 0.14 | 0.09 | 0.09 |
Gross Profit | 12.92 | 16.13 | 21.46 | 2.23 | 2.41 |
Selling, General & Admin | 26.67 | 26.54 | 33.56 | 10.81 | 8.54 |
Research & Development | 77.52 | 47.93 | 30.75 | 20.03 | 32.67 |
Operating Expenses | 104.2 | 74.47 | 64.31 | 30.85 | 41.21 |
Operating Income | -91.28 | -58.33 | -42.85 | -28.62 | -38.8 |
Interest Expense | -0.51 | -0.52 | -0.34 | -0.02 | -0.02 |
Interest & Investment Income | 13.85 | 15.87 | 5.21 | 0.02 | 0 |
Currency Exchange Gain (Loss) | 31.24 | -20.35 | 3.27 | 0.54 | -2.96 |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | 0 | 0.03 | -0 |
Pretax Income | -47.2 | -63.32 | -34.72 | -28.05 | -41.78 |
Income Tax Expense | 1.92 | 0.69 | 2.13 | 0.03 | 0.04 |
Earnings From Continuing Operations | -49.12 | -64.01 | -36.84 | -28.08 | -41.82 |
Minority Interest in Earnings | -0.01 | -0.01 | -0.12 | 0 | -0.01 |
Net Income | -49.13 | -64.02 | -36.96 | -28.08 | -41.83 |
Net Income to Common | -49.13 | -64.02 | -36.96 | -28.08 | -41.83 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 49 | 49 | 33 | 2 | 2 |
Shares Outstanding (Diluted) | 49 | 49 | 33 | 2 | 2 |
Shares Change | -0.27% | 48.38% | 1351.36% | - | - |
EPS (Basic) | -1.00 | -1.30 | -1.12 | -12.32 | -18.35 |
EPS (Diluted) | -1.00 | -1.30 | -1.12 | -12.32 | -18.35 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -76.4 | -70.81 | -30.17 | -24.2 | -44.16 |
Free Cash Flow Per Share | -1.56 | -1.44 | -0.91 | -10.61 | -19.37 |
Gross Margin | 98.91% | 99.14% | 99.36% | 96.16% | 96.55% |
Operating Margin | -698.86% | -358.51% | -198.43% | -1233.98% | -1554.37% |
Profit Margin | -376.16% | -393.47% | -171.14% | -1210.82% | -1675.92% |
Free Cash Flow Margin | -584.97% | -435.16% | -139.69% | -1043.60% | -1769.15% |
EBITDA | -89.76 | -56.83 | -42.17 | -28.19 | -38.66 |
EBITDA Margin | - | - | -195.25% | - | - |
D&A For EBITDA | 1.52 | 1.51 | 0.69 | 0.42 | 0.14 |
EBIT | -91.28 | -58.33 | -42.85 | -28.62 | -38.8 |
EBIT Margin | - | - | -198.43% | - | - |